Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Profit After Tax: 2016-2025

Historic Profit After Tax for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to -$231.8 million.

  • Summit Therapeutics' Profit After Tax fell 312.05% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$921.6 million, marking a year-over-year decrease of 368.59%. This contributed to the annual value of -$221.3 million for FY2024, which is 64.01% up from last year.
  • As of Q3 2025, Summit Therapeutics' Profit After Tax stood at -$231.8 million, which was up 59.03% from -$565.7 million recorded in Q2 2025.
  • Summit Therapeutics' Profit After Tax's 5-year high stood at -$19.2 million during Q4 2022, with a 5-year trough of -$565.7 million in Q2 2025.
  • For the 3-year period, Summit Therapeutics' Profit After Tax averaged around -$126.6 million, with its median value being -$60.4 million (2024).
  • In the last 5 years, Summit Therapeutics' Profit After Tax increased by 0.55% in 2023 and then tumbled by 836.84% in 2025.
  • Summit Therapeutics' Profit After Tax (Quarterly) stood at -$19.2 million in 2022, then plummeted by 90.17% to -$36.6 million in 2023, then slumped by 67.37% to -$61.2 million in 2024, then crashed by 312.05% to -$231.8 million in 2025.
  • Its Profit After Tax was -$231.8 million in Q3 2025, compared to -$565.7 million in Q2 2025 and -$62.9 million in Q1 2025.